Weight ManagementJuly 29, 2026·4 min read
By the CIRRUS Editorial Team — how we write and source this
Tirzepatide vs. semaglutide: how the two leading GLP-1 drugs actually differ
Both suppress appetite through incretin pathways, but they're not interchangeable — the dual-agonist mechanism behind tirzepatide changes the numbers.
Semaglutide (Wegovy, Ozempic) acts on a single receptor — GLP-1. Tirzepatide (Zepbound, Mounjaro) is a dual agonist, activating both GLP-1 and GIP receptors, and head-to-head trial data has consistently shown larger average weight loss with tirzepatide, on the order of several additional percentage points of body weight over comparable trial durations.
That doesn't make tirzepatide categorically 'better' for every patient — GI side effects (nausea, constipation) are common to both classes, dosing schedules differ, and insurance formularies frequently cover one and not the other, which in practice is often the deciding factor. Neither drug works without the dose titration schedule being followed; skipping steps to get to a higher dose faster increases side effect severity without improving outcomes.
For patients using either drug alongside oxygen or CPAP therapy, the relevant follow-up isn't which drug is more potent — it's scheduling the mask/interface refit and oxygen re-titration checkpoints as your weight actually changes, not on a generic calendar.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.